H. Kluger

James E. Clune, H. Kluger, B. Judson, 2020, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Melanoma brain metastases: is it time to reassess the bias?

S. Ariyan, J. Knisely, M. Sznol, 2011, Current problems in cancer.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Mark S. Anderson, J. Bluestone, S. Gettinger, 2018, Diabetes.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

V. Sondak, E. Lipson, M. Tetzlaff, 2022, Journal for ImmunoTherapy of Cancer.

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

J. Taube, T. Olencki, E. Lipson, 2021, Journal for ImmunoTherapy of Cancer.

First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70

David C. Smith, T. Owonikoko, H. Kluger, 2015, Cancer Chemotherapy and Pharmacology.

Complications associated with immunotherapy for brain metastases.

A. Omuro, H. Kluger, A. Huttner, 2019, Current opinion in neurology.

Clinical trials in melanoma patients with brain metastases

H. Kluger, V. Chiang, M. Yushak, 2015, Pigment cell & melanoma research.

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

S. Gettinger, M. Sznol, H. Kluger, 2015, Diabetes Care.

Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells

D. Hafler, H. Kluger, S. Weiss, 2021, Cancers.

Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases

M. Hurwitz, M. Sznol, H. Kluger, 2021, American journal of clinical oncology.

Why CTLA-4 Blockade Enhances Anti-Tumor Immunity

H. Kluger, J. Thumar, 2017 .

Ipilimumab: a promising immunotherapy for melanoma.

H. Kluger, J. Thumar, 2010, Oncology.

Adverse events induced by immune checkpoint inhibitors.

H. Kluger, K. Herold, A. Perdigoto, 2021, Current opinion in immunology.

Pre-treatment patient selection for nivolumab benefit based on serum mass spectra

R. Halaban, M. Sznol, H. Kluger, 2015, Journal of Immunotherapy for Cancer.

A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.

D. Davar, J. Kirkwood, H. Kluger, 2018 .

PERIPHERALLY-DERIVED AUTOLOGOUS T CELL THERAPY IN SOLID TUMOR PATIENTS

Shawn P. Carey, J. Fitzgerald, A. Shields, 2020 .

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

P. Hegde, J. Sosman, F. Hodi, 2019, Clinical Cancer Research.

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

J. Larkin, J. Kirkwood, H. Kluger, 2020 .

Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF

Abhijit A. Patel, D. Nguyen, S. Gettinger, 2021, JCO precision oncology.

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

H. Kluger, James B. Yu, V. Chiang, 2016, Cancer.

Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.

H. Kluger, M. J. Grant, Adebowale J. Adeniran, 2021, Clinical oncology, case reports.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

J. Wolchok, J. Larkin, M. Atkins, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single‐institution retrospective analysis with stratification of reactions by toxicity and implications for management

C. Ko, H. Kluger, M. Tomayko, 2019, Journal of the American Academy of Dermatology.

A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases

Upendra, Chiang, A. Vortmeyer, 2017 .

Title: Melanoma brain metastasis pseudoprogression after pembrolizumab treatment Running head: Brain pseudoprogression after pembrolizumab Authors:

A. Vortmeyer, H. Kluger, A. Mahajan, 2015 .

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes

Mark S. Anderson, Daniel B. Burkhardt, Smita Krishnaswamy, 2022, JCI insight.

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).

R. Motzer, T. Choueiri, W. Miller, 2020 .

Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?

H. Kluger, James B. Yu, V. Chiang, 2016, Journal of neurosurgery.

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL).

J. Wolchok, M. Atkins, J. Kirkwood, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

H. Kohrt, E. Lipson, H. Kluger, 2015 .

Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study.

B. Shuch, M. Hurwitz, H. Kluger, 2019, Clinical genitourinary cancer.

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

D. Rimm, R. Camp, H. Kluger, 2010, Clinical Cancer Research.

A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies.

J. Lee, M. Sznol, L. Devine, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

P. Wen, D. Cahill, P. Brastianos, 2022, Pigment cell & melanoma research.

Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.

James E. Clune, H. Kluger, K. Herold, 2020, Clinical oncology, case reports.

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

E. Meffre, H. Kluger, M. Tomayko, 2019, Journal of Immunotherapy for Cancer.

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

S. Ariyan, D. Rimm, M. Sznol, 2007, Journal of Translational Medicine.

Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism.

H. Kluger, G. Desir, H. Velázquez, 2016, Cancer research.

Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.

M. Sznol, H. Kluger, M. Burke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

J. Kirkwood, P. Hari, H. Kluger, 2022, Regular and Young Investigator Award Abstracts.

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

T. Choueiri, M. Fishman, M. Harrison, 2014 .

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

David C. Smith, T. Choueiri, M. Atkins, 2013 .

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

N. Shire, Diansong Zhou, H. Kluger, 2022, Frontiers in Immunology.

Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States.

H. Kluger, B. Judson, K. Olino, 2020, JAMA dermatology.

Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors

H. Kluger, S. Powell, R. Bindra, 2014, Molecular Cancer Therapeutics.

Vascularity of primary and metastatic renal cell carcinoma specimens

R. Camp, H. Kluger, J. Sznol, 2013, Journal of Translational Medicine.

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance

D. Rimm, M. Hurwitz, H. Kluger, 2022, Frontiers in Oncology.

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure

Y. Kluger, D. Hafler, M. Hurwitz, 2022, Molecular cancer.

Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy

L. Cantley, H. Kluger, M. Perazella, 2022, Journal for ImmunoTherapy of Cancer.

Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.

H. Kluger, J. Possick, Dale Han, 2017, Journal of immunotherapy.

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade

M. Gerstein, K. Syrigos, D. Rimm, 2022, NPJ precision oncology.

Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.

R. Herbst, A. Chiang, S. Gettinger, 2018 .

Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas

S. Ariyan, Hongyu Zhao, R. Halaban, 2004, Cancer Research.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

G. Gibney, R. Camp, H. Kluger, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Regulation of eIF2α by RNF4 promotes melanoma tumorigenesis and therapy resistance.

E. Ruppin, K. Brown, J. Lee, 2020, The Journal of investigative dermatology.

Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies

H. Kluger, J. Mehnert, 2012, Current Oncology Reports.

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions

D. Elder, R. Halaban, D. Rimm, 2008, Modern Pathology.

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

J. Wolchok, M. Dhodapkar, R. Halaban, 2015, The Journal of Immunology.

Melanoma: Clinical Presentations.

H. Kluger, N. Kibbi, Jennifer N Choi, 2016, Cancer treatment and research.

Chemotherapy and biologic therapies for melanoma: do they work?

H. Kluger, L. Jilaveanu, Lucia B. Jilaveanu, 2009, Clinics in dermatology.

Plasma Markers for Identifying Patients with Metastatic Melanoma

S. Ariyan, Y. Kluger, R. Halaban, 2011, Clinical Cancer Research.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Drew M. Pardoll, Janis M. Taube, Paul T. Nghiem, 2016, The New England journal of medicine.

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

M. Dhodapkar, M. Sznol, H. Kluger, 2014, Science Translational Medicine.

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer

Y. Kluger, D. Rimm, J. Giltnane, 2008, Breast Cancer Research.

Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma

Y. Kluger, D. Rimm, R. Camp, 2009, Clinical Cancer Research.

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

S. Ariyan, Krishna Kadaveru, M. Dhodapkar, 2016, JCI insight.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

Y. Kluger, R. Halaban, D. Rimm, 2014, Clinical Cancer Research.

Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer

Yuval Kluger, David L Rimm, Y. Kluger, 2008, Clinical Cancer Research.

Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer

H. Kluger, W. Zheng, S. Chambers, 2009, Oncogene.

Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis

D. Rimm, M. Dolled-Filhart, R. Camp, 2004, Clinical Cancer Research.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

David C. Smith, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PKCε Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at Mitochondria

T. Ideker, D. Rimm, H. Kluger, 2012, Cell.

Centrosomal Chk2 in DNA damage responses and cell cycle progession

H. Kluger, D. Stern, L. Tsvetkov, 2010, Cell cycle.

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

J. Larkin, J. Kirkwood, H. Kluger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Aaron M. Newman, A. Newman, M. Dhodapkar, 2018, The Journal of clinical investigation.

Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma.

Caroline H. Johnson, H. Kluger, S. Khan, 2021, European journal of cancer.

Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality

K. Syrigos, D. Rimm, H. Kluger, 2021, npj Precision Oncology.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy

H. Kluger, S. Topalian, P. Nghiem, 2018, Journal of Immunotherapy for Cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma

A. Belldegrun, M. Merino, B. Shuch, 2016, Proceedings of the National Academy of Sciences.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vertical pathway targeting in cancer therapy.

Joshua Sznol, H. Kluger, D. Shahbazian, 2012, Advances in pharmacology.

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.

Y. Kluger, D. Rimm, R. Camp, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A Role for ATF2 in Regulating MITF and Melanoma Development

L. Chin, N. Jones, S. Krajewski, 2010, PLoS genetics.

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

K. Flaherty, J. Kirkwood, K. Nathanson, 2014, Clinical Cancer Research.

Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.

R. Halaban, D. Rimm, H. Kluger, 2003, Cancer research.

MEK targeting in N-RAS mutated metastatic melanoma

H. Kluger, D. Shahbazian, L. Jilaveanu, 2014, Molecular Cancer.

C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas

D. Rimm, M. Sznol, R. Camp, 2009, Clinical Cancer Research.

Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells

James E. Clune, D. Hafler, K. Raddassi, 2021, The Journal of experimental medicine.

Circulating Clonally Expanded T Cells Reflect Functions of Tumor Infiltrating T Cells

James E. Clune, D. Hafler, K. Raddassi, 2020, bioRxiv.

Suppressor role of activating transcription factor 2 (ATF2) in skin cancer

P. Meltzer, S. Davis, N. Jones, 2008, Proceedings of the National Academy of Sciences.

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

R. Halaban, K. Schalper, M. Sznol, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Central Nervous System Metastases.

P. Brastianos, H. Kluger, J. Zuccato, 2021, Hematology/oncology clinics of North America.

Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.

H. Kluger, S. Higgins, V. Noronha, 2006, The Lancet. Oncology.

Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.

Y. Kluger, D. Rimm, R. Camp, 2005, Cancer research.

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).

S. Gettinger, M. Hurwitz, P. Hwu, 2020, Cancer discovery.

PLEKHA5 regulates tumor growth in metastatic melanoma

Y. Kluger, H. Kluger, M. Bosenberg, 2019, Cancer.

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

Y. Kluger, B. Shuch, H. Kluger, 2014, Journal of Cancer.

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors

Y. Kluger, R. Camp, H. Kluger, 2013, BMC Clinical Pathology.

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells

Valsamo Anagnostou, Robert Camp, G. Bepler, 2012, PloS one.

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

D. Rimm, V. Pelekanou, Jamaal A Rehman, 2017, Journal of Immunotherapy for Cancer.

Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry

D. Rimm, K. Schalper, V. Pelekanou, 2021, Clinical Cancer Research.

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

David C. Smith, M. Atkins, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Y. Kluger, R. Herbst, A. Chiang, 2020, The Lancet. Oncology.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

M. Hurwitz, P. Hwu, C. Hudgens, 2019, Cancer discovery.

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma

James E. Clune, S. Ariyan, M. Sznol, 2020, Journal for ImmunoTherapy of Cancer.

Genomic Heterogeneity and the Small Renal Mass

Patrick D. McGillivray, Garrett M. Dancik, Y. Kluger, 2018, Clinical Cancer Research.

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

H. Kluger, A. Elfiky, Michel Maira, 2011, Journal of Translational Medicine.

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors

Y. Kluger, B. Shuch, H. Kluger, 2015, BioMed research international.

Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

Jing Wang, Prathamesh M. Kulkarni, David L. Rimm, 2019, Clinical Cancer Research.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2016, Clinical Cancer Research.

Evolving Immunotherapy Approaches for Renal Cell Carcinoma

H. Kluger, S. Curtis, J. Cohen, 2016, Current Oncology Reports.

CD70 expression patterns in renal cell carcinoma.

R. Camp, H. Kluger, L. Jilaveanu, 2012, Human pathology.

Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy

H. Tawbi, H. Kluger, K. Margolin, 2019, Cutaneous Melanoma.

Vascularity of primary and metastatic renal cell carcinoma specimens

R. Camp, H. Kluger, J. Sznol, 2013, Journal of Translational Medicine.

Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping.

H. Kluger, Oluwarotimi S. Nettey, A. Alomari, 2015, Human pathology.

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma

R. Camp, H. Kluger, B. Escudier, 2014, Cancer Cell International.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

P. Hwu, M. Sznol, P. Ott, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma

P. Hwu, M. Sznol, H. Kluger, 2008 .

αB‐crystallin as a marker of lymph node involvement in breast carcinoma

D. Rimm, H. Kluger, A. Berger, 2004, Cancer.

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

James E. Clune, S. Ariyan, R. Salem, 2019, Journal of Immunotherapy for Cancer.

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases

K. Schalper, H. Kluger, J. Contessa, 2021, Journal for ImmunoTherapy of Cancer.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities

R. White, P. Wen, P. Brastianos, 2016, Pigment cell & melanoma research.

Advances in the systemic treatment of metastatic melanoma.

M. Sznol, H. Kluger, M. Yushak, 2013, Oncology.

Advances in therapy for melanoma brain metastases.

H. Kluger, L. Jilaveanu, Lucia B. Jilaveanu, 2013, Clinics in dermatology.

cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model

Joseph T. Chang, Y. Kluger, H. Kluger, 2004, Laboratory Investigation.

Frequent use of local therapy underscores need for multidisciplinary care in the management of patients with melanoma brain metastases treated with PD-1 inhibitors.

H. Kluger, James B. Yu, A. Mahajan, 2019, International journal of radiation oncology, biology, physics.

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma

D. Zelterman, D. Rimm, H. Kluger, 2019, Journal of Immunotherapy for Cancer.

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Daniel Zelterman, David L. Rimm, Balazs Acs, 2019, Clinical Cancer Research.

A phase 2 trial of dasatinib in advanced melanoma

M. Sznol, H. Kluger, A. Molinaro, 2011, Cancer.

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis

D. Nguyen, K. Politi, H. Kluger, 2019, Cell reports.

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

G. Shapiro, R. Kurzrock, H. Kluger, 2017, British Journal of Cancer.

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

K. Flaherty, J. Kirkwood, K. Nathanson, 2013, PloS one.

Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality

H. Kluger, G. Desir, R. Safirstein, 2019, Kidney international reports.

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models

Yuval Kluger, David L Rimm, Fabio Parisi, 2010, Breast Cancer Research.

Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series

James E. Clune, H. Kluger, K. Olino, 2020, JAAD case reports.

Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

K. Flaherty, K. Nathanson, D. Rimm, 2009, Clinical Cancer Research.

HSP90 as a marker of progression in melanoma.

Y. Kluger, D. Rimm, R. Camp, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

K. Flaherty, D. Rimm, R. Camp, 2010, Human pathology.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

J. Kirkwood, H. Kluger, K. Lewis, 2021, Journal of Clinical Oncology.

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

D. Rimm, M. Sznol, Lieping Chen, 2015, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis

M. Aboian, H. Kluger, James B. Yu, 2021, Journal of Neuro-Oncology.

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

K. Flaherty, J. Kirkwood, K. Nathanson, 2015, Clinical Cancer Research.

Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

Rajarsi R. Gupta, J. Saltz, R. Vanguri, 2021, Scientific reports.

Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer

David L Rimm, D. Rimm, R. Camp, 2005, Clinical Cancer Research.

Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis.

P. Humphrey, A. Kibel, B. Shuch, 2021, American journal of clinical pathology.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

C. Horak, J. Wolchok, M. Atkins, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

Betty Y. S. Kim, P. Brown, K. Hess, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases

A. Vortmeyer, A. Chiang, S. Gettinger, 2016, Cancer Immunology Research.

Systemic Immunotherapy for the Treatment of Brain Metastases

H. Kluger, J. Cohen, 2016, Front. Oncol..

PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?

B. Shuch, R. Camp, H. Kluger, 2014, Journal of Clinical Pathology.

Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study

S. Ariyan, R. Halaban, D. Rimm, 2004, Melanoma research.

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

Ming-zhu Yin, A. Iwasaki, K. Blenman, 2021, Nature.

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling

K. Syrigos, D. Rimm, S. Warren, 2019, Clinical Cancer Research.

Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer

D. Rimm, M. Sznol, R. Camp, 2005, Clinical Cancer Research.

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

A. Iwasaki, K. Blenman, M. Sznol, 2021, Nature.

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

P. Ascierto, M. Atkins, J. Sosman, 2023, Journal for ImmunoTherapy of Cancer.

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

H. Tawbi, R. Ferris, N. Rizvi, 2023, Journal for ImmunoTherapy of Cancer.

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Vanessa M. Hubbard-Lucey, J. Taube, R. Sullivan, 2020, Journal for ImmunoTherapy of Cancer.

Results of a Phase II Placebo‐controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small‐cell Lung Carcinoma

H. Kluger, D. Ramies, B. Hellerstedt, 2019, Clinical lung cancer.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas

James E. Clune, S. Ariyan, O. Bláha, 2023, Frontiers in Oncology.

Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma

K. Flaherty, R. Halaban, D. Rimm, 2006, Clinical Cancer Research.

Rab33A: characterization, expression, and suppression by epigenetic modification.

S. Ariyan, R. Halaban, H. Kluger, 2006, The Journal of investigative dermatology.

Drug targets and predictive biomarkers in the management of metastatic melanoma

H. Kluger, J. Thumar, E. Giesen, 2012, Pharmacogenomics and personalized medicine.

A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

R. Sullivan, P. Ascierto, R. Halaban, 2017, Cancer Immunology Research.

Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

G. Linette, Melissa L. Johnson, M. Edelman, 2019, Clinical Trials.

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

J. Larkin, J. Kirkwood, H. Kluger, 2019, Journal of Clinical Oncology.

Assessment of PI3 kinase as a druggable target in melanoma

K. Flaherty, D. Rimm, R. Camp, 2007 .

P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

M. Hurwitz, P. Hwu, M. Sznol, 2017 .

Molecular alternations in uveal melanoma.

H. Kluger, M. Materin, M. Faries, 2011, Current problems in cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

The Treatment of Melanoma Brain Metastases

H. Kluger, N. Kibbi, 2016, Current Oncology Reports.

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Yuval Kluger, David L Rimm, Gabriela Turcu, 2017, Clinical Cancer Research.

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

Lieping Chen, R. Camp, H. Kluger, 2015, Oncotarget.

Integrated Analysis of Tumor Samples Sheds Light on Tumor Heterogeneity

Yuval Kluger, Peining Li, Mariann Micsinai, 2012, The Yale journal of biology and medicine.

Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2015 .

From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

H. Kluger, S. Weiss, 2017, Cancer journal.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R af Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

M. Hurwitz, P. Hwu, C. Hudgens, 2019 .

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

D. Rimm, H. Kluger, M. Bates, 2019, Journal of Immunotherapy for Cancer.

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

Y. Kluger, R. Camp, H. Kluger, 2014, Oncotarget.

SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth

Kazuhiro Iwai, Oleksiy Klymenko, H. Kluger, 2017, The Journal of clinical investigation.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Xin Victoria Wang, Keith T Flaherty, J. Manola, 2017, Clinical Cancer Research.

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

R. Motzer, T. Choueiri, W. Miller, 2022, Journal for immunotherapy of cancer.

Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.

K. Bromberg, S. Krajewski, H. Kluger, 2007, Cancer research.

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases

H. Kluger, V. Neumeister, K. Heishima, 2020, Journal of Neuro-Oncology.

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy

D. Nguyen, H. Kluger, A. Mahajan, 2019, Journal of Immunotherapy for Cancer.

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy

D. Rimm, H. Kluger, J. Zugazagoitia, 2020, Oncoimmunology.

Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma

David L Rimm, Marisa Dolled-Filhart, D. Rimm, 2004, Cancer Research.

VEGF, VEGFR1, and VEGFR2 expression in melanoma

K. Flaherty, D. Rimm, M. Sznol, 2007 .

Comparing available criteria for measuring brain metastasis response to immunotherapy

H. Kluger, A. Tsiouris, James B. Yu, 2017, Journal of Neuro-Oncology.

Ablation of Histone Demethylase KDM5B in Melanoma Augments Anti-Tumor Immunity through Upregulation of Retroelements

A. Iwasaki, K. Blenman, M. Sznol, 2020 .

PKC ε regulates ATF 2 availability to alter mitochondrial permeability following genotoxic stress

T. Ideker, D. Rimm, H. Kluger, 2013 .

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors

J. Barrett, M. Hurwitz, H. Tawbi, 2023, Journal for ImmunoTherapy of Cancer.

Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review

M. Sznol, H. Kluger, Jacob S. Heng, 2022, BMJ Open Ophthalmology.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

G. Gibney, R. Camp, H. Kluger, 2013 .

Dhodapkar NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Induction of Antigen-Specific Immunity with a Vaccine Targeting

M. Dhodapkar, M. Sznol, H. Kluger, 2014 .

Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity

D. Peters, A. Sinusas, H. Kluger, 2021, PloS one.

Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma

D. Rimm, K. Blenman, H. Kluger, 2018, Clinical Research (Excluding Clinical Trials).

A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.

M. Hurwitz, P. Hwu, M. Sznol, 2017 .

1212TiPPIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

M. Hurwitz, P. Hwu, M. Sznol, 2017 .

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

J. Larkin, N. Ibrahim, S. Gettinger, 2018 .

Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.

A. Vortmeyer, R. Herbst, A. Chiang, 2015 .

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

C. Horak, J. Wolchok, M. Sznol, 2013 .

Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2010 .

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

P. Ross-Macdonald, T. Choueiri, M. Fishman, 2015, Journal of Immunotherapy for Cancer.

Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).

K. Flaherty, G. Shapiro, H. Kluger, 2013 .

Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).

J. Kirkwood, H. Tawbi, L. Butterfield, 2015 .

Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients

R. Halaban, M. Sznol, I. Melero, 2016 .

Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.

D. Nguyen, H. Kluger, A. Mahajan, 2018 .

1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL.

T. Choueiri, M. Fishman, M. Harrison, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten−/− melanoma

H. Kluger, M. Bosenberg, Z. Ronai, 2013, Oncogene.

Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.

M. Sznol, L. D. Del Priore, H. Kluger, 2019, Ophthalmology.

Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

G. Linette, S. Grupp, H. Kluger, 2016 .

Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells

M. Sznol, R. Camp, C. Angeletti, 2008, Laboratory Investigation.

Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.

M. Lotze, H. Kluger, B. Curti, 2017 .

Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

N. Rizvi, H. Kluger, M. Callahan, 2016 .

Validation of the prognostic utility of the gene expression profiling test in patients with uveal melanoma.

Alison X. Chan, M. Goldbaum, M. Sznol, 2023, Ophthalmology.

Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.

N. Rizvi, H. Kluger, M. Callahan, 2017 .

Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma.

P. Hwu, M. Sznol, H. Kluger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microvessel density as a prognostic marker in high-risk renal cell carcinoma.

Xin Victoria Wang, Robert S. DiPaola, J. Manola, 2017 .

Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.

M. Hurwitz, P. Hwu, M. Tetzlaff, 2017 .

Reply to A. Shinde et al.

H. Tawbi, H. Kluger, G. Long, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.

A. Vortmeyer, M. Sznol, H. Kluger, 2015 .

Determinants of overall survival in patients with metastatic uveal melanoma.

M. Sznol, A. Shoushtari, C. Barker, 2023, Cancer.

Survival in Breast Cancer High HSP 90 Expression Is Associated with Decreased Updated

Y. Kluger, D. Rimm, J. Giltnane, 2007 .

Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.

M. Hurwitz, M. Sznol, H. Kluger, 2023, Clinical genitourinary cancer.

MET Inhibition in Clear Cell Renal Cell Carcinoma

B. Shuch, H. Kluger, Zongzhi Z. Liu, 2016, Journal of Cancer.

Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial

K. Flaherty, J. Kirkwood, K. Nathanson, 2012 .

Studies of NVP-BEZ235 in melanoma.

H. Kluger, L. Jilaveanu, Lucia B. Jilaveanu, 2013, Current cancer drug targets.

187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours

A. Jimeno, S. Gettinger, H. Kluger, 2021, Journal of Thoracic Oncology.

Characterizing disease states from topological properties of transcriptional regulatory networks

David Tuck, Yuval Kluger, Harriet Kluger, 2006, BMC Bioinformatics.

Increased Expression of the E 3 Ubiquitin Ligase RNF 5 Is Associated with Decreased Survival in Breast Cancer

K. Bromberg, S. Krajewski, H. Kluger, 2007 .

A phase II trial of dasatinib in advanced melanoma.

M. Sznol, H. Kluger, L. Rink, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

M. Suarez‐Almazor, D. Hafler, H. Tawbi, 2020 .

127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patients

H. Kluger, J. Warrell, T. Aung, 2022, Regular and Young Investigator Award Abstracts.

A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.

M. Sznol, H. Kluger, J. Weber, 2020 .

C-met as a therapeutic target using ARQ 197 in renal cell carcinoma.

G. Gibney, R. Camp, H. Kluger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma: Clinical Presentations.

H. Kluger, N. Kibbi, Jennifer N. Choi, 2016 .

Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer

Y. Kluger, D. Rimm, R. Camp, 2008, Clinical Cancer Research.

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

D. Rimm, R. Camp, H. Kluger, 2010, Clinical Cancer Research.

Ipilimumab-induced perforating colitis.

Kisha Mitchell, M. Sznol, H. Kluger, 2013, Journal of clinical gastroenterology.

PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?

B. Shuch, R. Camp, H. Kluger, 2014, Journal of Clinical Pathology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Plasma Markers for Identifying Patients with Metastatic Melanoma

S. Ariyan, Y. Kluger, R. Halaban, 2011, Clinical Cancer Research.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

J. Taube, T. Olencki, E. Lipson, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation

H. Freeze, H. Kluger, Z. Ronai, 2015, Science Signaling.

Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer

S. Ariyan, M. Sznol, H. Kluger, 2008, Journal of immunotherapy.

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

H. Kluger, D. Ramies, B. Hellerstedt, 2012 .

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis

D. Nguyen, K. Politi, H. Kluger, 2019, Cell reports.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

J. Manola, K. Flaherty, R. DiPaola, 2017, Clinical Cancer Research.

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

M. Suarez‐Almazor, D. Hafler, H. Tawbi, 2022, Journal of Clinical Oncology.

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

R. Sullivan, J. Sosman, H. Tawbi, 2023, Journal for ImmunoTherapy of Cancer.

Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.

H. Kluger, S. Jessel, M. Austin, 2021, Clinical oncology, case reports.

Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib.

H. Kluger, M. Burke, E. Lilly, 2015, JAMA dermatology.

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

S. Ariyan, C. Schmidt, D. Rimm, 2007, Journal of Translational Medicine.